Castle Biosciences Expands Its Reach with Dual Listing on Nasdaq Texas

Castle Biosciences, Inc., recognized for its innovative testing solutions guiding patient care, has officially announced that it has been granted approval for a dual listing on Nasdaq Texas, a newly established exchange located in Dallas. The company, which maintains its primary listing on The Nasdaq Global Market, is now set to also list on Nasdaq Texas under the same ticker symbol, "CSTL." This development is significant for Castle, reinforcing its commitment to innovation and growth within the healthcare sector, especially in its home state of Texas.

Commitment to Texas and Innovation

With its roots firmly planted in Texas, Castle Biosciences serves a dual purpose: enhancing patient care while bolstering the local economy. Derek Maetzold, the company’s president and CEO, emphasized that the dual listing signifies not only their continued growth but also their dedication to Texas as a thriving hub for life sciences innovation. According to Maetzold, the move will help strengthen their connection to the local communities and facilitate the recruitment of top talent essential for their operations and growth.

"Castle was founded in Texas and remains deeply connected to the state's communities, talent and innovation ecosystem," stated Maetzold. The dual listing is anticipated to bolster investor engagement and enhance Castle's visibility as a key player in the life sciences sector.

Rachel Racz, president of Nasdaq Texas, expressed her excitement regarding Castle’s participation, stating, "Castle Biosciences is the kind of company Nasdaq Texas was built for: innovative, growth-oriented, and forward-looking in every sense.” This reflects Nasdaq Texas's mission to support firms that possess strong regional ties, enabling them to thrive in an increasingly competitive marketplace.

Dual Listing Benefits

The dual listing on Nasdaq Texas is not merely a logistical change; it symbolizes new opportunities for Castle. Frank Stokes, the CFO of Castle Biosciences, highlighted that the additional listing facilitates increased interaction with investors while preserving their primary listing. This strategic addition is expected to augment the company’s visibility and align with Texas’s ongoing development as a prominent business and innovation hub.

Investors in Castle need not worry; this new listing will not impact the trading of their common stock nor alter the company's operational or financial structures. The dual listing is designed to create a seamless experience without affecting existing shareholder interests.

About Castle Biosciences

Castle Biosciences focuses on developing and providing innovative diagnostic tests aimed at guiding patient care, particularly within dermatologic and gastroenterological diseases. The firm creates actionable solutions that enhance disease management, striving for better patient outcomes. Their patient-first philosophy stands at the core of their operations, empowering both patients and healthcare professionals to make informed decisions backed by robust scientific research and advanced molecular testing.

The company’s portfolio includes trademarked tests such as DecisionDx-Melanoma and DecisionDx-SCC, illustrating their commitment to delivering personalized care solutions. For healthcare professionals, these tools are vital in crafting effective treatment plans tailored to individual patient needs.

As Castle Biosciences forges ahead with its dual listing, it stands poised to make a more significant impact in the healthcare landscape, reinforcing the connection between Texas and innovation in life sciences. For more insights into their offerings and vision, one can visit Castle Biosciences.

With this move, Castle Biosciences not only expands its operational footprint but also plays a pivotal role in showcasing Texas as a stronghold for innovation in the healthcare sector, ensuring it remains at the forefront of advancements in patient care solutions.